Section 3.9 – Exemption for possession or use of cannabis to treat a qualifying illness.
Effective 3/17/2021 58-37-3.9. Exemption for possession or use of cannabis to treat a qualifying illness. (1) As used in this section: (a) “Cannabis” means marijuana. (b) “Cannabis product” means the same as that term is defined in Section 26-61a-102. (c) “Drug paraphernalia” means the same as that term is defined in Section 58-37a-3. (d) “Medical […]
Section 4 – Schedules of controlled substances — Schedules I through V — Findings required — Specific substances included in schedules.
Effective 5/4/2022 58-37-4. Schedules of controlled substances — Schedules I through V — Findings required — Specific substances included in schedules. (1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section. (2) Schedules I, II, III, IV, and V […]
Section 4.2 – Listed controlled substances.
Effective 5/12/2020 58-37-4.2. Listed controlled substances. The following substances, their analogs, homologs, and synthetic equivalents are listed controlled substances: (1) AB-001; (2) AB-PINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide; (3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide; (4) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide); (5) ADB-CHMINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1- (cyclohexylmethyl)indazole-3-carboxamide); (6) ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1oxobutan-2-yl)-1- (4-fluorobenzyl)-1H-indazole-3-caboxamide); (7) AKB48; (8) alpha-Pyrrolidinohexanophenone (alpha-PHP) (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one); (9) alpha-Pyrrolidinovalerophenone (alpha-PVP); (10) AM-694 (1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone); (11) AM-1248; (12) AM-2201 […]
Section 5.5 – Recognized controlled substance analogs.
58-37-5.5. Recognized controlled substance analogs. (1) A substance listed under Subsection (2) is an analog, as defined in Subsection 58-37-2(1)(g), if the substance, in any quantity, and in any material, compound, mixture, or preparation, is present in: (a) any product manufactured, distributed, or possessed for the purpose of human consumption; or (b) any product, the […]
Section 6 – License to manufacture, produce, distribute, dispense, administer, or conduct research — Issuance by division — Denial, suspension, or revocation — Records required — Prescriptions.
Affected by 63I-1-258 on 7/1/2032 Effective 5/4/2022 58-37-6. License to manufacture, produce, distribute, dispense, administer, or conduct research — Issuance by division — Denial, suspension, or revocation — Records required — Prescriptions. (1) (a) The division may adopt rules relating to the licensing and control of the manufacture, distribution, production, prescription, administration, dispensing, conducting of […]
Section 6.5 – Continuing education for controlled substance prescribers.
Effective 3/17/2021 58-37-6.5. Continuing education for controlled substance prescribers. (1) For the purposes of this section: (a) “Controlled substance prescriber” means an individual, other than a veterinarian, who: (i) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah Controlled Substances Act; and (ii) possesses the authority, in accordance with the individual’s […]
Section 7 – Labeling and packaging controlled substance — Informational pamphlet for opiates.
Effective 5/8/2018 58-37-7. Labeling and packaging controlled substance — Informational pamphlet for opiates. (1) A person licensed pursuant to this act may not distribute a controlled substance unless it is packaged and labeled in compliance with the requirements of Section 305 of the Federal Comprehensive Drug Abuse Prevention and Control Act of 1970. (2) No […]
Section 8 – Prohibited acts — Penalties.
Effective 5/4/2022 58-37-8. Prohibited acts — Penalties. (1) Prohibited acts A — Penalties and reporting: (a) Except as authorized by this chapter, it is unlawful for a person to knowingly and intentionally: (i) produce, manufacture, or dispense, or to possess with intent to produce, manufacture, or dispense, a controlled or counterfeit substance; (ii) distribute a […]
Section 8.5 – Applicability of Title 76 prosecutions under this chapter.
58-37-8.5. Applicability of Title 76 prosecutions under this chapter. Unless specifically excluded in or inconsistent with the provisions of this chapter, the provisions of Title 76, Chapter 1, General Provisions, Chapter 2, Principles of Criminal Responsibility, Chapter 3, Punishments, and Chapter 4, Inchoate Offenses, are fully applicable to prosecutions under this chapter. Enacted by Chapter […]
Section 3.8 – Enforcement.
Effective 9/23/2019 58-37-3.8. Enforcement. (1) A law enforcement officer, as that term is defined in Section 53-13-103, except for an officially designated drug enforcement task force regarding conduct that is not in accordance with Title 26, Chapter 61a, Utah Medical Cannabis Act, may not expend any state or local resources, including the officer’s time, to: […]